Thrombolytic therapy in cardiac arrest caused by cardiac etiologies or presumed pulmonary embolism: An updated systematic review and meta-analysis

Omar A. Alshaya BSc, Pharm, PharmD, BCPS1,2,3 | Abdulrahman I. Alshaya BSc, Pharm, PharmD, BCPS, BCCCP1,2,3 | Hisham A. Badreldin BSc, Pharm, PharmD, BCPS, BCCP, FCCP1,2,3 | Sarah T. Albalawi1 | Sarah T. Alghonaim1 | Majed S. Al Yami BSc, Pharm, PharmD, BCPS1,2,3

1Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
2Pharmaceutical Care Services, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia
3King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

Abstract

Background: Many cardiac arrest cases are encountered annually worldwide, with poor survival. The use of systemic thrombolysis during cardiopulmonary resuscitation for the treatment of cardiac arrest remains controversial.

Objectives: Evaluate the safety and efficacy of systemic thrombolysis in patients with cardiac arrest due to presumed or confirmed pulmonary embolism or cardiac etiology.

Methods: We searched the PubMed and Cochrane databases from inception through April 2021 to identify relevant randomized controlled trials and observational studies. The primary efficacy and safety outcomes were survival to hospital discharge and reported bleeding, respectively. Sensitivity analysis was performed on the basis of study design and etiology of cardiac arrest.

Results: Eleven studies were included, with 4696 patients (1178 patients received systemic thrombolysis, and 3518 patients received traditional therapy). There was a higher rate of survival to hospital discharge in patients who received systemic thrombolysis versus no systemic thrombolysis (risk ratio [RR], 1.35; 95% confidence interval [CI], 0.95-1.91). There were also higher rates of survival at 24 hours (RR, 1.24; 95% CI, 0.97-1.59) and hospital admission (RR, 1.53; 95% CI, 1.04-2.24), and return of spontaneous circulation (ROSC) (RR, 1.34; 95% CI, 1.05-1.71) with the use of systemic thrombolysis. Impacts on survival to discharge and survival at 24 hours were not statistically significant. Patients receiving systemic thrombolysis had a 65% increase in bleeding events compared with no systemic thrombolysis (RR, 1.65; 95% CI, 1.20-2.27).

Conclusion: Systemic thrombolysis in cardiac arrest did not improve survival to hospital discharge and led to more bleeding events. However, it increased the rates of hospital admission and ROSC achievement.
Essentials

- Blood clots are a cause of cardiac arrest, and can be treated with clot-busting medications (thrombolytics).
- We studied the benefits of these medications in patients with cardiac arrest aged ≥16 years.
- Thrombolytics did not improve survival to hospital discharge and increased bleeding.

1 | INTRODUCTION

In the United States, >350,000 individuals develop cardiac arrest each year, with poor survival rates. The predominant causes of cardiac arrest are pulmonary embolism (PE) and acute myocardial infarction (AMI), both of which can be treated with intravenous thrombolysis. In the United States, survival rates to hospital discharge were only 10.4% for out-of-hospital cardiac arrest (OHCA) and 25.8% for in-hospital cardiac arrest (IHCA). In Europe, survival to hospital discharge was only 8% in OHCA, based on data from 27 countries, and 18.4% in IHCA from one prospective study representing 144 hospitals in the United Kingdom.2,3

Evidence on the outcomes of thrombolytic therapy in patients with cardiac arrest has revealed a minimal impact on hospital mortality. In a previous randomized controlled trial (RCT) of patients with cardiac arrest due to cardiac etiologies, there was no observed difference in overall survival with the use of systemic thrombolysis with an increased risk of bleeding.4 This finding was also supported by a Canadian RCT that compared thrombolytic therapy with placebo in patients with pulseless electrical activity (PEA) and cardiac arrest and showed no beneficial effect of thrombolysis.5 Thrombolytic agents and their dosing have been heavily debated over the past decade, given their use to treat presumed AMI or PE; however, current guidelines endorse the use of thrombolysis in cardiac arrest secondary to presumed PE with weak recommendations.6–8

Most studies that investigated thrombolysis in undifferentiated PEA were suspected but not necessarily confirmed PE.4,5,9 The most recent meta-analysis by Wang et al.10 evaluated nine studies with a total of 4384 patients with cardiac arrest. They concluded an increased risk of bleeding secondary to systemic thrombolysis administration with no significant improvement in survival to hospital discharge. However, a recent large registry-based analysis from France that included 14,253 patients found better 30-day mortality outcomes in patients with cardiac arrest who received thrombolysis.11 One major factor that could explain these inconsistent findings is the level of certainty of practitioners’ diagnoses of PE or AMI in cardiac arrest cases. The objective of this meta-analysis was to provide an updated evaluation of the safety and efficacy of systemic thrombolysis in patients presenting with cardiac arrest due to presumed or confirmed PE or cardiac etiology.

2 | METHODS

A comprehensive systematic review was conducted using the PubMed and Cochrane databases from inception through April 2021 to identify studies that investigated the safety and efficacy of thrombolysis during cardiac arrest of presumed PE or cardiac etiologies. The search was conducted using medical subject headings and keywords for cardiopulmonary resuscitation (CPR), heart arrest, OHCA, thrombolytic therapy, and tissue plasminogen activator. We also searched the references of the identified studies to identify any other relevant studies for inclusion. The review process adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.12

Studies were considered eligible for inclusion if thrombolytic therapy was administered during CPR, if the study included adults ≥16 years of age, if data were extracted from original studies published in English, and if the study evaluated at least one of the predetermined primary and secondary outcomes of this study. Studies were excluded if thrombolysis was administered before or after CPR, if data were not compared to a control group, or if data were presented as conference abstracts.

The identified studies of interest were reviewed and assessed against the inclusion criteria by three reviewers (OA, SB, and SG). Data pertaining to the clinical outcomes of interest were extracted and reviewed for quality and accuracy by two authors (OA and AA). The risk of bias for each study was assessed using the Cochrane Collaboration Risk of Bias Assessment Tool 2.0 for RCTs and the Newcastle-Ottawa Scale (NOS) for observational cohort studies.13,14 The NOS awards up to nine stars for observational cohort studies: four stars for the selection of included patients, two stars for comparability of cohorts based on the design and analysis, and three stars for the assessment of outcomes and adequacy of follow-up. The quality of the included observational cohort studies was determined based on the number of stars obtained: low quality: 0 to 3, medium quality: 4 to 6, and high quality: 7 to 9. Two authors (OA and AA) assessed the quality of included studies. If there was a disagreement, a third experienced author was consulted to reach a consensus. The following data were collected from each study: study authors, publication year, study design, etiology of cardiac arrest, thrombolytic agent used, dose, adjunctive therapy, number of patients in the treatment and control groups, and clinical outcomes of interest. This study was exempted from ethical approval by the institutional review board at King Abdullah International Medical Research Center.
was assessed using 2 statistics. Heterogeneity effects model was used as studies looked at different patient inclusion criteria and were included. Eleven studies met our inclusion criteria and were included. One study identified from the relevant references was a post hoc analysis of an RCT, 2 were observational prospective studies, and 5 were observational retrospective studies. All observational studies compared their treatment with that of a control arm. The details of each study, including the systemic thrombolysis regimen used, are summarized in Table 1. The quality of the included studies was assessed, and the results are presented in Table 2. Overall, the included RCTs were considered strong evidence with a low risk for bias, and observational studies were deemed moderate to high quality.

### 3.3 Summary of the included studies

The role of alteplase during CPR was investigated in patients with OHCA who did not achieve ROSC within 15 minutes due to cardiac reasons. Two patients who received alteplase developed gastric ulcer bleeding and required blood transfusion. ROSC was achieved in 68% of the patients in the treatment group (n = 40) and in 44% of the controls (n = 50; P = .03).

Another study included patients who developed OHCA due to nontraumatic etiologies (AMI in 60.2% and PE in 17.6%). ROSC was achieved in 70.4% of the alteplase group (n = 108) compared with 51% of the control group (n = 216; P = .001). Bleeding complications from autopsy results showed that six patients in the alteplase group had bleeding and seven in the controls.

In 2002, an RCT was conducted to investigate the role of alteplase in cardiac arrest occurring either outside the hospital or in the emergency department due to unknown or presumed cardiovascular causes. The primary outcome of survival to hospital discharge was achieved in only one patient in the treatment group (n = 117) and no patients in the control group (n = 116; P = .99).

Additionally, the bleeding complications were investigated in a retrospective study involving 66 patients (36 patients receiving alteplase and 30 control patients). Major bleeding occurred more frequently with alteplase administration than in the controls (25% vs 10%; P = .15).

In 2004, another RCT investigated the role of tenecteplase (50-mg bolus) in patients with OHCA (n = 19) compared with a placebo group (n = 16). ROSC was achieved in 42% and 6% of the treatment and control groups, respectively (95% CI, 11-61).

Similarly, in a study involving 163 patients (50 receiving systemic thrombolysis and 113 controls), tenecteplase was associated with increased ROSC achievement compared with controls (26% vs 12.4%; P = .04).

In a post hoc analysis, the effect of alteplase on hospital admission (99 receiving alteplase, 1087 controls) was assessed. More hospital admissions were achieved with alteplase than with controls (45.5% vs 32.7%; P = .01).

In 2008, the Thrombolysis in Cardiac Arrest (TROICA) study was conducted in patients with OHCA who were randomly assigned to receive tenecteplase (n = 525) or placebo (n = 525). The 30-day survival rate did not differ between the two groups (14.7% with tenecteplase and 17% with placebo; P = .36).
**Table 1** Characteristics of included studies in the meta-analysis

| Study            | Year | Design  | Etiology       | Thrombolytic agent | Dose           | Adjunctive therapy | Number of patients, thrombolysis/control | Outcomes                                                                 |
|------------------|------|---------|----------------|-------------------|----------------|--------------------|------------------------------------------|--------------------------------------------------------------------------|
| Böttiger         | 2001 | Prospective | Cardiac       | Alteplase         | 50-mg bolus (repeat if needed) | Heparin              | 40/50                                    | • Survival to hospital discharge (RR, 1.88; 95% CI, 0.57-6.19)  |
|                  |      |         |                |                   |                |                     |                                          | • Survival at 24 h (RR, 1.59; 95% CI, 0.81-3.11) |
|                  |      |         |                |                   |                |                     |                                          | • Hospital admission (RR, 1.92; 95% CI, 1.16-3.16) |
|                  |      |         |                |                   |                |                     |                                          | • ROSC (RR, 1.53; 95% CI, 1.05-2.24)   |
|                  |      |         |                |                   |                |                     |                                          | • Bleeding (RR, 6.22; 95% CI, 0.31-125.98)  |
| Lederer          | 2001 | Retrospective | Nontraumatic  | Alteplase         | 100 mg (15-mg bolus, followed by 50-mg infusion over 30 min and 35 mg over 60 min) | Heparin + Aspirin    | 108/216                                  | • Survival to hospital discharge (RR, 1.62; 95% CI, 1.03-2.55) |
|                  |      |         |                |                   |                |                     |                                          | • Survival at 24 h (RR, 1.46; 95% CI, 1.11-1.92) |
|                  |      |         |                |                   |                |                     |                                          | • ROSC (RR, 1.45; 95% CI, 1.21-1.73)     |
|                  |      |         |                |                   |                |                     |                                          | • Bleeding (RR, 0.88; 95% CI, 0.32-2.41) |
| Abu-Laban        | 2002 | RCT     | Cardiac        | Alteplase         | 100 mg over 15 min | Heparin, aspirin, or both | 117/116                                  | • Survival to hospital discharge (RR, 2.97; 95% CI, 0.12-72.27)         |
|                  |      |         |                |                   |                |                     |                                          | • Survival at 24 h (RR, 8.92; 95% CI, 0.49-163.90) |
|                  |      |         |                |                   |                |                     |                                          | • Hospital admission (RR, 1.16; 95% CI, 0.40-3.34) |
|                  |      |         |                |                   |                |                     |                                          | • ROSC (RR, 0.92; 95% CI, 0.57-1.48)    |
|                  |      |         |                |                   |                |                     |                                          | • Bleeding (RR, 2.97; 95% CI, 0.31-28.18) |
| Janata           | 2003 | Retrospective | PE            | Alteplase         | 0.6-1 mg/kg (max, 100 mg) | Heparin            | 36/30                                   | • Survival to hospital discharge (RR, 2.92; 95% CI, 0.65-13.01)         |
|                  |      |         |                |                   |                |                     |                                          | • Survival at 24 h (RR, 2.26; 95% CI, 1.10-4.64) |
|                  |      |         |                |                   |                |                     |                                          | • ROSC (RR, 1.54; 95% CI, 0.96-2.46)     |
|                  |      |         |                |                   |                |                     |                                          | • Bleeding (RR, 2.50; 95% CI, 1.14-5.49)  |
| Fatovich         | 2004 | RCT     | Cardiac        | Tenecteplase      | 50-mg bolus      | Not specified       | 19/16                                   | • Survival to hospital discharge (RR, 0.84; 95% CI, 0.06-12.42)         |
|                  |      |         |                |                   |                |                     |                                          | • Hospital admission (RR, 1.68; 95% CI, 0.17-16.91) |
|                  |      |         |                |                   |                |                     |                                          | • ROSC (RR, 6.74; 95% CI, 0.94-48.29)   |
| Bozeman          | 2006 | Prospective | Cardiac        | Tenecteplase      | Ranged from 30 to 50 mg (mean, 0.54 mg/kg; range, 0.26-0.77 mg/kg) | Heparin            | 50/113                                  | • Survival to hospital discharge (RR, 11.18; 95% CI, 0.55-228.64)       |
|                  |      |         |                |                   |                |                     |                                          | • Survival at 24 h (RR, 11.18; 95% CI, 0.55-228.64) |
|                  |      |         |                |                   |                |                     |                                          | • Hospital admission (RR, 29.06; 95% CI, 1.67-506.11) |
|                  |      |         |                |                   |                |                     |                                          | • ROSC (RR, 2.10; 95% CI, 1.07-4.13)    |
|                  |      |         |                |                   |                |                     |                                          | • Neurological status (RR, 11.18; 95% CI, 0.55-228.64) |
|                  |      |         |                |                   |                |                     |                                          | • Bleeding (RR, 15.65; 95% CI, 0.82-297.38)  |
| Stadlbauer       | 2006 | Post-hoc analysis | Nontraumatic | Tenecteplase or reteplase | Variable - depends on participating center | Heparin            | 99/1087                                 | • Survival to hospital discharge (RR, 1.49; 95% CI, 0.89-2.51)         |
|                  |      |         |                |                   |                |                     |                                          | • Hospital admission (RR, 1.39; 95% CI, 1.10-1.76) |

**Notes:**
- **Böttiger** and **Lederer** used alteplase.
- **Abu-Laban** used alteplase with an additional bolus and infusion.
- **Fatovich** used tenecteplase.
- **Bozeman** used tenecteplase with a range of doses.
- **Stadlbauer** used tenecteplase or reteplase depending on the center.

**Adjunctive therapy** for some studies included heparin and aspirin or both, with variable dosages across studies.
| Study         | Year | Design  | Etiology     | Thrombolytic agent                  | Dose                                      | Adjunctive therapy | Number of patients, thrombolysis/control | Outcomes                                                                 |
|--------------|------|---------|--------------|-------------------------------------|-------------------------------------------|--------------------|-------------------------------------------|--------------------------------------------------------------------------|
| Böttiger     | 2008 | RCT     | Cardiac      | Tenecteplase                         | Weight-based dosing: <60 kg, 30 mg; 60-69 kg, 35 mg; 70-79 kg, 40 mg; 80-89 kg, 45 mg; ≥90 kg, 50 mg | None               | 525/525                                   | Survival to hospital discharge (RR, 0.86; 95% CI, 0.65-1.14) 30-day survival (RR, 0.87; 95% CI, 0.65-1.14) Survival at 24 h (RR, 0.92; 95% CI, 0.77-1.10) Hospital admission (RR, 0.97; 95% CI, 0.87-1.09) ROSC (RR, 1.01; 95% CI, 0.90-1.12) Neurological status (RR, 1.12; 95% CI, 0.88-1.42) Bleeding (RR, 1.53; 95% CI, 1.02-2.30) |
| Renard       | 2011 | Retrospective | Nontraumatic | Alteplase or tenecteplase | Alteplase: 50-mg bolus Tenecteplase: 100-UI/kg bolus | Not specified      | 107/1154                                   | Hospital admission (RR, 2.02; 95% CI, 1.62-2.53) |
| Yousuf       | 2016 | Retrospective | PE           | Alteplase                           | 100 mg                                    | Not specified      | 19/23                                     | Survival to hospital discharge (RR, 1.21; 95% CI, 0.19-7.80) Survival at 24 h (RR, 0.99; 95% CI, 0.52-1.87) Bleeding (RR, 3.63; 95% CI, 0.41-32.13) |
| Javaudn      | 2019 | Retrospective | PE           | Alteplase, tenecteplase, or streptokinase | Alteplase: median dose of 50 mg (50-80 mg) Tenecteplase: median dose of 45 mg (35-50 mg) Streptokinase: dose unknown | Not specified      | 58/188                                    | Survival at 24 h (RR, 1.04; 95% CI, 0.84-1.30) 30-day survival (RR, 2.43; 95% CI, 1.08-3.67) Neurological status (RR, 2.16; 95% CI, 0.80-5.82) Bleeding (RR, 1.08; 95% CI, 0.30-3.86) |

Abbreviations: CI, confidence interval; PE, pulmonary embolism; RCT, randomized controlled trial; ROSC, return of spontaneous circulation; RR, risk ratio.
After the TROICA study, Renard et al. evaluated the effect of systemic thrombolysis (alteplase 50-mg intravenous [IV] bolus or tenecteplase 100 UI/kg IV bolus) (n = 107) compared with controls (n = 1154) on survival to hospital admission. A higher number of patients achieved the primary outcome with treatment compared with controls (47.7% vs 23.6%; P < .001).

In 2016, a single-center retrospective study of alteplase in cardiac arrest due to presumed PE found that patients who received 100 mg IV alteplase (n = 19) were not statistically different from the controls (n = 23) in terms of survival to hospital discharge (10.5% vs 8.7%; P = 1.00).21

Recently, Javaudin et al. investigated the benefit of systemic thrombolysis in OHCA due to a diagnosis of PE confirmed on hospital admission in a large retrospective multicenter study in France. The systemic thrombolysis group (n = 58) achieved a higher 30-day survival rate than the control group (n = 188) (16% vs 6%; P = .005).

### 3.4 | Primary outcomes

#### 3.4.1 | Survival to hospital discharge

Nine studies were pooled to compare this outcome with a total of 3148 patients, of which 1005 patients received systemic thrombolysis and 2143 patients were in the control group. Higher rates of survival to hospital discharge across all study designs were observed in patients who received systemic thrombolysis than in those who did not receive systemic thrombolysis, but the difference was not statistically significant (RR, 1.35; 95% CI, 0.95-1.91), with moderate-level heterogeneity (I² = 33.6%; P = .15; Figure 2A). These results were different based on RCTs only data, as the rates of survival to hospital discharge were lower by 13% in patients who received systemic thrombolysis compared with those who did not receive systemic thrombolysis. In a subgroup analysis based on the cause of cardiac arrest, survival to
TABLE 2  Quality assessment of included studies

Newcastle-Ottawa Scale for assessing the quality of included cohort studies

| Study                  | Böttiger, 2001 | Lederer, 2001 | Janata, 2003 | Bozeman, 2006 | Stadlbauer, 2006 | Renard, 2011 | Yousuf, 2016 | Javaudin, 2019 |
|------------------------|----------------|---------------|--------------|----------------|------------------|--------------|--------------|----------------|
| Selection              |                |               |              |                |                  |              |              |                |
| Representativeness of   | –              | –             | *            | –              | –                | –            | –            | –              |
| exposed cohort         |                |               |              |                |                  |              |              |                |
| Selection of nonexposed| –              | –             | –            | –              | –                | *            | –            | –              |
| cohort                 |                |               |              |                |                  |              |              |                |
| Ascertainment of        | *              | –             | –            | *              | –                | *            | –            | –              |
| exposure               |                |               |              |                |                  |              |              |                |
| Demonstration that      | *              | *             | *            | *              | –                | *            | *            | *              |
| outcome of interest was |                |               |              |                |                  |              |              |                |
| not present at start    |                |               |              |                |                  |              |              |                |
| of study               |                |               |              |                |                  |              |              |                |
| Comparability on basis  | *              | *             | –            | –              | –                | *            | *            | *              |
| of design and analysis  |                |               |              |                |                  |              |              |                |

The Cochrane Risk of Bias tool for assessing the quality of included RCTs

| Study                  | Abu-Laban, 2002 | Fatovich, 2004 | Böttiger, 2008 |
|------------------------|-----------------|----------------|----------------|
| Random assignment       | Low risk        | Low risk       | Low risk       |
| Allocation concealment  | Low risk        | Low risk       | Low risk       |
| Blinding of participants| Low risk        | Low risk       | Low risk       |
| Blind evaluation for    | Low risk        | Low risk       | Low risk       |
| outcomes               | Low risk        | Low risk       | Low risk       |
| Incomplete outcome data | Low risk        | Low risk       | Low risk       |
| Selective reporting     | Low risk        | Low risk       | Low risk       |
| Other bias              | Low risk        | Low risk       | Low risk       |

Abbreviation: RCTs, randomized controlled trials.

FIGURE 2  Rates of primary outcomes between cardiac arrest patients who received thrombolysis versus no thrombolysis during CPR across all study designs. (A) Rates of survival to hospital discharge; (B) rates of any reported bleeding. CI, confidence interval; CPR, cardiopulmonary resuscitation; RCT, randomized controlled trial; RR, risk ratio.
**FIGURE 3** Rates of primary outcomes between patients with cardiac arrest who received thrombolysis versus no thrombolysis during CPR across all causes of cardiac arrest. (A) Rates of survival to hospital discharge; (B) rates of any reported bleeding. CI, confidence interval; CPR, cardiopulmonary resuscitation; RCT, randomized controlled trial; RR, risk ratio

**FIGURE 4** Rates of secondary outcomes between cardiac arrest patients who received thrombolysis versus no thrombolysis during CPR across all study designs. (A) Rates of survival at 24 h; (B) rates of hospital admission; (C) rates of ROSC. CI, confidence interval; CPR, cardiopulmonary resuscitation; RCT, randomized controlled trial; ROSC, return of spontaneous circulation; RR, risk ratio
hospital discharge was significantly higher in patients with nontraumatic causes who received systemic thrombolysis than in those who did not (RR, 1.56; 95% CI, 1.11-2.20) (Figure 3A).

### 3.4.2 Reported bleeding

Nine of the included studies reported data on bleeding after systemic thrombolysis. There were a total of 1998 patients, in which 902 patients received systemic thrombolysis and 1096 patients received traditional therapy. The use of systemic thrombolysis across all study designs was associated with a significant incremental risk in reported bleeding events as compared with no systemic thrombolysis (RR, 1.65; 95% CI, 1.20-2.27) with low-level heterogeneity ($I^2 = 0.0\%$; $P = .44$; Figure 2B). These results were more driven by data from RCTs that showed significantly higher incidence of bleeding in patients who received systemic thrombolysis versus those who did not receive systemic thrombolysis (RR, 1.56; 95% CI, 1.05-2.33). In a subgroup analysis based on the cause of cardiac arrest, any reported bleeding was significantly higher in patients with PE who received systemic thrombolysis than in those who did not (RR, 2.09; 95% CI, 1.10-3.96; Figure 3B).

### 3.5 Secondary outcomes

#### 3.5.1 Survival at 24 hours

This outcome was evaluated in eight studies. A total of 2195 patients were included in our analysis, of which 945 patients received systemic thrombolysis and 1250 were in the control group. There was a trend favoring higher rates of survival at 24 hours in patients who received systemic thrombolysis compared with those who did not receive systemic thrombolysis (RR, 1.24; 95% CI, 0.97-1.59), with moderate to high-level heterogeneity ($I^2 = 60.7\%; P = .01$; Figure 4A). These results were also consistent on the basis of data from RCTs that showed a 78% increase in the rates of survival at 24 hours in patients who received systemic thrombolysis as compared to no systemic thrombolysis (RR, 1.78; 95% CI, 0.23-13.64).

#### 3.5.2 Hospital admission

This outcome was assessed in seven of the included studies with a total of 4018 patients. The number of patients who received systemic thrombolysis was 957, and the number of patients in the control group was 3061. Significantly higher rates of hospital admission were observed in patients who received systemic thrombolysis than those who did not (RR, 1.53; 95% CI, 1.04-2.24) with high-level heterogeneity ($I^2 = 86.5\%; P = <.001$; Figure 4B). However, data from RCTs did not show significant benefit regarding hospital admission among the group that received systemic thrombolysis versus no systemic thrombolysis (RR, 0.98; 95% CI, 0.87-1.09).

#### 3.5.3 Return of spontaneous circulation

Seven of the included studies examined the achievement of ROSC with systemic thrombolysis compared with the controls in a total of 1947 patients. Systemic thrombolysis and traditional therapy were administered in 885 and 1062 patients, respectively. Significantly higher rates of ROSC were observed with the use of systemic thrombolysis than with no systemic thrombolysis (RR, 1.34; 95% CI, 1.05-1.71) with moderate- to high-level heterogeneity ($I^2 = 73.1\%$; $P = .001$; Figure 4C). The results from the RCTs did not show a significant difference in ROSC achievement among patients who received systemic thrombolysis as compared with those who did not receive systemic thrombolysis (RR, 1.04; 95% CI, 0.72-1.51).

---

**Figure 5** Rates of secondary outcomes between patients with cardiac arrest who received thrombolysis versus no thrombolysis during CPR across all study designs. (A) Rates of survival at 30 days; (B) rates of neurological outcomes. CI, confidence interval; CPR, cardiopulmonary resuscitation; RCT, randomized controlled trial; RR, risk ratio.
3.5.4 | Survival at 30 days

This outcome was assessed in only 2 of the 11 included studies with a total of 1296 patients. Systemic thrombolysis and traditional therapy were administered in 538 and 713 patients, respectively. Higher rates of survival at day 30 were observed among patients who received systemic thrombolysis versus those who did not (RR, 1.35; 95% CI, 0.49-3.67) with high-level heterogeneity ($I^2 = 82\%$; $P = .02$; Figure 5A).

3.5.5 | Neurological outcomes

This important outcome was assessed in only 3 of the 11 included studies with a total of 591 patients. Systemic thrombolysis and traditional therapy were administered to 194 and 397 patients, respectively. The use of systemic thrombolysis resulted in higher rates of achieving acceptable neurological outcomes than no systemic thrombolysis (RR, 1.60; 95% CI, 0.72-3.53) with moderate-level heterogeneity ($I^2 = 50.8\%$; $P = .13$; Figure 5B).

3.5.6 | Publication bias

No publication bias was identified as shown in the funnel plots for primary outcomes (Figure 6).

4 | DISCUSSION

The results of this updated systematic review and meta-analysis showed that patients who received thrombolytic therapy following cardiac arrest due to presumed pulmonary embolism or cardiac causes had higher rates of survival to hospital discharge, survival at 24 hours, and survival at 30 days than those who did not receive systemic thrombolysis; however, these results were not statistically significant. On the other hand, the use of thrombolytic therapy in this subset of patients was associated with a higher risk of reported bleeding. This significant increase in the risk of bleeding was consistent among RCTs. Achieving higher rates of ROSC and attaining higher rates of hospital admission were the main observed benefits of thrombolytic therapy; however, these results were mainly driven by observational studies. In patients with confirmed PE-related cardiac arrest, thrombolytic therapy was associated with a twofold increase in the risk of bleeding.

Over the years, and because of the experience gained in this field, it has been proposed that thrombolytic therapy during CPR may help stabilize hemodynamics. The suggested theory of the potential benefit of thrombolytic therapy in these patients emerged from experimental studies that showed that thrombolytic therapy during cardiac arrest might enhance microcirculatory reperfusion. These findings indicate that during reperfusion after cardiac arrest, blood coagulation is markedly activated without sufficient endogenous fibrinolysis. Thrombolytic therapy may be indicated because of the extensive coagulation activation and subsequent fibrin formation responsible for inducing microcirculatory reperfusion disorders.22

This meta-analysis differed from that previously published by Wang et al.10 We added two large studies that have recently been published in this field to the literature. In this regard, the meta-analysis by Wang et al did not show any significant improvement in hospital discharge, ROSC, or 24-hour survival rates. In contrast, our meta-analysis showed a beneficial effect of thrombolytic therapy in achieving higher ROSC rates and hospital admissions. This may have contributed to enhanced microcirculation. However, earlier achievement of ROSC did not affect the mortality rate. Previous evidence suggests that close to 70% of individuals who achieve ROSC ultimately die from several
complications such as post–cardiac arrest syndrome. However, we believe that early achievement of ROSC could provide more time to explore further advanced treatment modalities such as but not limited to mechanical circulatory support systems.

Similar to Wang et al, and owing to the inconsistent definition of bleeding events among the included studies, we did not evaluate the bleeding outcome based on the bleeding event category. Our findings are also in line with those of Wang et al, who reported that the use of systemic thrombolysis was associated with a significantly increased risk of any reported bleeding. Our analysis did not show any improvement in neurological outcomes in the patients who received systemic thrombolysis.

Our study had several limitations that need to be highlighted. First, our analysis included a small number of RCTs. In addition, there were inconsistencies among the included studies in terms of reported outcomes. Furthermore, the patient population included both patients with PE and patients without PE, which we attempted to minimize by evaluating PE-related studies in a subgroup analysis. Moreover, when we performed the analysis mainly on the included RCTs, there were no differences in the clinical outcomes of interest, except for the increased risk of bleeding in patients who received systemic thrombolysis. We believe that large and well-designed RCTs are warranted to ascertain the relationship between thrombolytic therapy and potential benefits among patients with cardiac arrest. Second, the included studies carried many confounders that are extremely difficult to control, which might affect the net benefit of thrombolytic therapy, such as the definitive diagnosis, dose and duration of thrombolytic therapy, and other supportive and adjunctive therapies. Finally, indication bias for analyses involving observational data could have affected the overall results of the clinical outcomes of interest.

5 | CONCLUSION

In this updated systematic review and meta-analysis, the use of systemic thrombolysis was not associated with an increase in survival to hospital admission, ROSC achievement, and more bleeding events. Rigorous and high-quality RCTs are required to confirm these findings.

AUTHOR CONTRIBUTIONS

All authors participated equally in generating the research idea, conducting the search strategy, reviewing the collected studies for inclusion or exclusion, performing the analysis, writing the manuscript, and reviewing it for the completeness of information.

RELATIONSHIP DISCLOSURE

The authors have no conflicts of interest to declare.

ORCID

Omar A. Alshaya https://orcid.org/0000-0002-2244-0491

TWITTER

Omar A. Alshaya @omaraalshaya
Abdulrahman I. Alshaya @_aalshaya
Hisam A. Badreldin @87HiSHAM
Sarah T. Albalawi @sarahbl
Sarah T. Alghonaim @SaraAlghonaim
Majed S. Al Yami @MajedSalehAlYami

REFERENCES

1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. doi:10.1161/CIR.0000000000000757
2. Gräsner JT, Wnent J, Herlitz J, et al. Survival after out-of-hospital cardiac arrest in Europe - results of the EuReCa TWO study. Resuscitation. 2020;148:218-226. doi:10.1016/j.resuscitation.2019.12.042
3. Nolan JP, Soar J, Smith GB, et al. Incidence and outcome of inhospital cardiac arrest in the United Kingdom National Cardiac Arrest Audit. Resuscitation. 2014;85(8):987-992. doi:10.1016/j.resuscitation.2014.04.002
4. Böttiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008;359(25):2651-2662. doi:10.1056/NEJMoa070570
5. Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. N Engl J Med. 2002;346(20):1522-1528. doi:10.1056/NEJMoa012885
6. Soar J, Berg KM, Andersen LW, et al. Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation. 2020;156:80-119. doi:10.1016/j.resuscitation.2020.09.012
7. Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: adult basic and advanced life support: 2020 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020;142(16_suppl_2):S366-S468. doi:10.1161/CIR.0000000000000916
8. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021;167:115-151. doi:10.1016/j.resuscitation.2021.02.010
9. Stadlbauer KH, Krismer AC, Arntz HR, et al. Effects of thrombolysis during out-of-hospital cardiopulmonary resuscitation. Am J Cardiol. 2006;97(3):305-308. doi:10.1016/j.amjcard.2005.08.045
10. Wang Y, Wang M, Ni Y, Liang B, Liang Z. Can systemic thrombolysis improve prognosis of cardiac arrest patients during cardiopulmonary Resuscitation? A systematic review and meta-analysis. J Emerg Med. 2019;57(4):478-487. doi:10.1016/j.jemermed.2019.07.011
11. Javauadin F, Lascarrou JB, Le Bastard Q, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest caused by pulmonary embolism increases 30-day survival: findings from the French National Cardiac Arrest registry. Chest. 2019;156(6):1167-1175. doi:10.1016/j.chest.2019.07.015
12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
13. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605. doi:10.1007/s10654-010-9491-z
15. Lederer W, Lichtenberger C, Pechlaner C, Kroesen G, Baubin M. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. *Resuscitation*. 2001;50(1):71-76. doi:10.1016/s0300-9572(01)00317-3
16. Janata K, Holzer M, Kürkciyan I, et al. Major bleeding complications in cardiopulmonary resuscitation: the place of thrombolytic therapy in cardiac arrest due to massive pulmonary embolism. *Resuscitation*. 2003;57(1):49-55. doi:10.1016/s0300-9572(02)00430-6
17. Fatovich DM, Dobb GJ, Clugston RA. A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial). *Resuscitation*. 2004;61(3):309-313. doi:10.1016/j.resuscitation.2004.01.016
18. Bozeman WP, Kleiner DM, Ferguson KL. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. *Resuscitation*. 2006;69(3):399-406. doi:10.1016/j.resuscitation.2005.09.027
19. Böttiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. *Lancet*. 2001;357(9268):1583-1585. doi:10.1016/S0140-6736(00)04726-7
20. Renard A, Verret C, Jost D, et al. Impact of fibrinolysis on immediate prognosis of patients with out-of-hospital cardiac arrest. *J Thromb Thrombolysis*. 2011;32(4):405-409. doi:10.1007/s11239-011-0619-0
21. Yousuf T, Brinton T, Ahmed K, et al. Tissue plasminogen activator use in cardiac arrest secondary to fulminant pulmonary embolism. *J Clin Med Res*. 2016;8(3):190-195. doi:10.14740/jocmr2452w
22. Böttiger BW, Martin E. Thrombolytic therapy during cardiopulmonary resuscitation and the role of coagulation activation after cardiac arrest. *Curr Opin Cardiol*. 2001;7(3):176-183. doi:10.1097/0000000000000006
23. Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. *JAMA*. 2006;295(1):50-57. doi:10.1001/jama.295.1.50
24. Nolan JP, Laver SR, Welch CA, Harrison DA, Gupta V, Rowan K. Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC case mix programme database. *Anaesthesia*. 2007;62(12):1207-1216. doi:10.1111/j.1365-2044.2007.05232.x
25. Miyazaki K, Hikone M, Kuwahara Y, Ishida T, Sugiyama K, Hamabe Y. Extracorporeal CPR for massive pulmonary embolism in a “hybrid 2136 emergency department”. *Am J Emerg Med*. 2019;37(12):2132-2135. doi:10.1016/j.ajem.2019.01.039
26. Scott JH, Gordon M, Vender R, et al. Venoarterial extracorporeal membrane oxygenation in massive pulmonary embolism-related cardiac arrest: a systematic review. *Crit Care Med*. 2021;49(5):760-769. doi:10.1097/CCM.0000000000004828

How to cite this article: Alshaya OA, Alshaya AI, Badreldin HA, Albalawi ST, Alghonaim ST, Al Yami MS. Thrombolytic therapy in cardiac arrest caused by cardiac etiologies or presumed pulmonary embolism: An updated systematic review and meta-analysis. *Res Pract Thromb Haemost*. 2022;6:e12745. doi:10.1002/rth2.12745